8-K: Expion360 Secures $1.1M, Appoints New CEO & Chairman

Expion360 Inc. completed a $1.1 million private placement and announced significant leadership changes, including a new CEO and Chairman.

Summary

• Expion360 Inc. completed a private placement on October 16, 2025, raising approximately $1.1 million in net proceeds.
• The private placement involved the sale of 613,077 shares of common stock at $1.65 per share and pre-funded warrants for up to 144,498 shares at $1.6499 per warrant share, with an exercise price of $0.001.
• Proceeds will be used for severance obligations to former executive officers, working capital, and general corporate purposes.
• Brian Schaffner resigned as CEO but will remain on the Board and provide consulting services until January 31, 2026, receiving a severance package.
• Paul Shoun resigned as President and Chairman of the Board, receiving a severance package and COBRA benefits.
• Joseph Hammer was appointed as the new Chief Executive Officer and Chairman of the Board, with an annual base salary of $330,000.
• Scott Burell was appointed as an independent director and to the Compensation Committee, increasing the Board size from five to six.
• Shawna Bowin and Carson Heagen each received 100,000 fully vested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding and the new leadership brings relevant experience, which are positive. However, the substantial severance costs and potential dilution from the private placement introduce some negative aspects, balancing the overall sentiment to moderately positive.

Positives

• Successfully raised approximately $1.1 million in net proceeds through a private placement, enhancing liquidity.
• Appointment of Joseph Hammer as CEO and Chairman brings extensive investment and strategic experience from LHX Corp. and LH Financial.
• Appointment of Scott Burell as an independent director and to the Compensation Committee strengthens corporate governance and brings significant financial and public life sciences company experience.
• Existing directors George Lefevre, Tien Q. Nguyen, and Steven M. Shum will remain on the Board, providing continuity.

Negatives

• Significant severance payments to former CEO Brian Schaffner and former President and Chairman Paul Shoun, including 24 months of base salary and 100,000 fully vested RSUs each, represent substantial costs.
• The issuance of new shares and warrants in the private placement may result in dilution for existing shareholders.
• Capital raise proceeds are being used to cover severance obligations, which are operational costs rather than direct growth investments.

Risks

• Securities (shares and warrants) were issued under an exemption from registration, meaning they may have restrictions on resale if not covered by an effective registration statement or Rule 144.
• The issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which could be substantial under certain market conditions.
• Hedging activities by purchasers of the Securities could negatively impact the market price of the company's publicly-traded securities and reduce the value of existing stockholders' equity interests.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes, including severance obligations. The new leadership appointments suggest a strategic re-direction or strengthening of the company's executive and board functions.

Management Comments

• Brian Schaffner's resignation is not the result of any disagreement with respect to the Company’s operations, policies, or practices.
• Paul Shoun's resignation is not the result of any disagreement with respect to the Company’s operations, policies, or practices.
• The company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions.
• The company acknowledges that its obligations under the Transaction Documents are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the company may have against any Purchaser.

Industry Context

Expion360 operates in an industry likely related to lithium-based battery or storage systems, as indicated by the non-compete clause for the new CEO. The appointment of a new CEO with a background in investment and strategic guidance, along with an independent director experienced in public life sciences companies, suggests a focus on strategic growth, potentially through mergers, acquisitions, or new investment opportunities, aligning with broader trends of consolidation and innovation in the energy storage and related technology sectors.

Comparison to Industry Standards

• The filing does not provide specific financial or operational data to compare against global benchmarks or specific comparable companies/projects.
• The new independent director, Scott Burell, has experience with companies like Trailblazer Merger Corporation I (Nasdaq: TBMC), AIVITA Biomedical, Inc., CombiMatrix Corporation (Nasdaq: CBMX), Microbot Medical, Inc. (Nasdaq: MBOT), and DIH Holding US, Inc. (Nasdaq: DHAI), which are in healthcare finance, immuno-oncology, medical devices, and physical rehabilitation robotics. This indicates a diverse background for the new director, but no direct comparison points for Expion360's specific business are provided.

Management Changes

Corporate Governance

Related Party Transactions

• The lead investor in the Private Placement, Pioneer Capital Anstalt, is advised by Joseph Hammer and LHX Corp. Joseph Hammer was simultaneously appointed as the new CEO and Chairman of the Board of Expion360 Inc.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants. The capital raise provides funding, but the use of proceeds for severance and working capital rather than direct growth initiatives might be viewed differently. New leadership could bring strategic changes.
• Employees: Significant changes in top leadership (CEO, President, Chairman) could impact employee morale or strategic direction. The granting of RSUs to Shawna Bowin and Carson Heagen could be seen as a retention incentive.
• Customers/Suppliers: No direct impact mentioned, but new leadership might lead to shifts in business strategy or operational focus.
• Creditors: The capital raise improves the company's financial position and liquidity, which is generally positive for creditors.

Next Steps

• Brian Schaffner will provide consulting services to the company until January 31, 2026, to assist with the transition of his roles.
• Joseph Hammer's annual bonus award will be set no later than six months following the effective date of his employment agreement.
• The company will apply to list all newly issued shares and warrant shares on its Trading Market.
• The company will maintain the listing or quotation of its Common Stock on the Trading Market.
• The company will timely file a Form D with respect to the Securities and take action to qualify the Securities for sale under applicable state securities laws.
• George Lefevre, Tien Q. Nguyen, and Steven M. Shum will remain as directors until at least the next annual meeting of shareholders.

Key Dates

Recommendation

The capital raise provides immediate liquidity and the appointment of a new CEO and independent director with relevant experience could signal a positive strategic shift. However, the substantial severance costs for outgoing executives and the potential for dilution from the private placement introduce uncertainties. Investors should hold to observe the execution of the new leadership's strategy and the impact of these changes on future financial performance before making further investment decisions.

Keywords

Expion360, Private Placement, CEO Appointment, Board Changes, Pre-Funded Warrants, Capital Raise, Management Transition, Corporate Governance, XPON, Lithium Battery